Clinical Trial

The Nicotinic Cholinergic System and Cognitive Aging

Study Description

The Nicotinic Cholinergic System and Cognitive Aging

Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a subset of receptors called the nicotinic system plays in cognition in healthy non-demented older adults (referred to as normal cognitive aging). This is critical because the ever growing healthy aging population will show declines in cognition that fall short of dementia but still impact functional abilities and independence. Maintaining good nicotinic system functioning throughout adulthood may lessen the cognitive symptoms of aging. At this time, it is not clear what the biological cause of age-related changes in cognition is. This study will examine the role of the nicotinic system in the healthy aging brain and examine its role in memory and thinking processes in older and younger adults.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Nicotine patch, oral mecamylamine, placebo

Each participant randomly receives one active drug or placebo on each of three study days.

Additional Information

Official Study Title

The Nicotinic Cholinergic System and Cognitive Aging

Clinical Trial ID

NCT03408574

ParticipAid ID

DbD3Aa